Inicio › Cáncer de pulmón de células no pequeñas › Illinois › Waukegan
Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Waukegan, IL
16 estudios para Cáncer de pulmón de células no pequeñas buscan participantes en centros de Waukegan y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutandoFase 3
- AMG Libertyville - Oncology, Libertyville · A 8 mi de distancia
- Condell Memorial Hospital, Libertyville · A 8 mi de distancia
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ReclutandoFase 3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · A 7 mi de distancia
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · A 10 mi de distancia
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ReclutandoFase 2
- City of Hope Chicago, Zion · A 6 mi de distancia
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
ReclutandoFase 3
- Advocate Medical Group - Libertyville Oncology, Libertyville · A 8 mi de distancia
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
ReclutandoFase 3
- Captain James A. Lovell Federal Health Care Center, North Chicago · A 3 mi de distancia
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
ReclutandoFase 3
- City of Hope® Cancer Center Chicago, Zion · A 6 mi de distancia
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
ReclutandoFase 3
- Research Site, Zion · A 6 mi de distancia
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
ReclutandoFase 3
- Research Site, North Chicago · A 3 mi de distancia
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
ReclutandoFase 3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · A 7 mi de distancia
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · A 10 mi de distancia
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
ReclutandoFase 3
- Cancer Treatment Centers of America (CTCA), Zion · A 6 mi de distancia
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutandoFase 2
- Northwestern Medicine Lake Forest Hospital, Lake Forest · A 7 mi de distancia
- AMG Libertyville - Oncology, Libertyville · A 8 mi de distancia
- Condell Memorial Hospital, Libertyville · A 8 mi de distancia
- y 1 más
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2
- Northwestern Medicine Lake Forest Hospital, Lake Forest · A 7 mi de distancia
- AMG Libertyville - Oncology, Libertyville · A 8 mi de distancia
- Condell Memorial Hospital, Libertyville · A 8 mi de distancia
- y 1 más
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2/3
- Northwestern Medicine Lake Forest Hospital, Lake Forest · A 7 mi de distancia
- AMG Libertyville - Oncology, Libertyville · A 8 mi de distancia
- Condell Memorial Hospital, Libertyville · A 8 mi de distancia
- y 1 más
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2
- Northwestern Medicine Lake Forest Hospital, Lake Forest · A 7 mi de distancia
- Northwestern Medicine Grayslake Outpatient Center, Grayslake · A 10 mi de distancia
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
ReclutandoFase 2
- City of Hope at Chicago, Zion · A 6 mi de distancia
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
ReclutandoEstudio observacional
- AMG Libertyville - Oncology, Libertyville · A 8 mi de distancia
- Condell Memorial Hospital, Libertyville · A 8 mi de distancia
Ensayos de Cáncer de pulmón de células no pequeñas en otras ciudades
- Houston, TX145 estudios
- New York City, NY121 estudios
- Arlington, VA104 estudios
- Nashville, TN97 estudios
- Boston, MA90 estudios
- Los Angeles, CA87 estudios
- St. Louis, MO73 estudios
- Chicago, IL61 estudios
- Baltimore, MD60 estudios
- San Antonio, TX59 estudios
- Columbus, OH57 estudios
- Washington, DC55 estudios
Otros estudios en Waukegan
- Cáncer de pulmón16 estudios
- Cáncer de seno12 estudios
- Colitis ulcerativa7 estudios
- Cáncer de riñón (carcinoma de células renales)7 estudios
- Cáncer de ovario6 estudios
- Cáncer metastásico6 estudios
- Carcinoma de células escamosas de cabeza y cuello6 estudios
- Cáncer del colon y del recto6 estudios
- Cáncer de próstata6 estudios
- Melanoma5 estudios
- Leucemia mielógena aguda5 estudios
- Enfermedad de Crohn5 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.